Corporate spinoffs are the transactions where a parent company separates a business unit into a new public company and distributes the shares to its own stockholders, and the academic record on them is unusually consistent: as a group, they beat the broader market in the years after separation. The finding has survived decades of study and a wide range of market conditions, which is why the category keeps showing up in newsletter pitches. The question is never whether the category works; it is which individual names deserve the label.
The Evidence Base
The research on spinoffs stretches back decades, and the conclusion holds across eras and datasets. Studies from investment banks and universities have repeatedly found that spinoffs outperform the broad market and, just as important, that they outperform the newly public companies that reach the market through initial public offerings. The edge tends to show up in the first one to three years after the carve-out, which is exactly the window when forced selling and management change work their way through the shareholder base. Our What Stansberry Research Won’t Tell You About Marshank’s… explainer covers this in detail.
Part of the gap is definitional. An IPO is a sale, staged by underwriters, priced to build demand and often to leave an early pop on the table for insiders and favored accounts. A spinoff is a distribution with no underwriter and no roadshow. There is no one marketing the new shares, and the first owners are the parent’s shareholders, many of whom do not want them. The two sets of conditions could hardly be more different, and the returns have reflected that for as long as the two have been measured side by side.
Orphan Selling, Quantified
The mechanism that drives early spinoff weakness, then recovery, is not a mystery. When the new shares are distributed, index funds whose benchmark is the parent sell because the new name is not in their index. Style and mandate funds sell because the new company does not fit their box, often because it sits below their minimum market value. Retail holders sell because they never asked for a second stock.
That wave of selling arrives all at once, in the first days and weeks of trading, and it is blind to fundamentals. The result is a price that undershoots the business’s worth for reasons that have nothing to do with the business itself. As the sellers exhaust themselves and longer-term investors step in, the price repairs. This is the orphan-sale effect, and it is the single most repeatable source of the spinoff trade’s edge. Gabe Marshank’s Market Maven presentation leans on exactly this dynamic, arguing that after 2026’s heavy IPO calendar, the spinoffs reaching the market are the better risk-adjusted trade.
Spinoffs Versus IPOs After the Aftershock
Marshank’s framing adds a timing layer to the standard evidence. He describes the 2026 IPO wave and its “aftershock” as the setup that makes spinoffs attractive now: a glut of new listings absorbs capital and attention, while the quieter carve-outs arrive unloved and underpriced. Whether the specific names live up to the historical average is a separate question from whether the historical average is real. It mostly is, and a different take on the same evidence appears in our earlier spinoff primer.
The distinction matters because it separates the thesis you can verify from the picks you have to judge one at a time. A category that beats the market on average still contains plenty of individual losers, and no presentation can wish those away with a historical chart. The base definition of the transaction lives in our company spinoff explainer, and how to sort the winners from the losers is covered in our spinoff stocks guide.
The Bottom Line
Corporate spinoffs have a real, well-documented tendency to outperform, driven by a mix of better focus and mechanical orphan selling. The evidence is the strongest part of the pitch, and it survives scrutiny. The weaker part is always the translation from category to specific names, because a historical average tells you nothing about whether the particular carve-out in front of you is a good business at a fair price. Know the evidence, then do the name-by-name work anyway.
The Lifecycle of a Spinoff Trade
The trade itself has a recognizable shape. Before the distribution date, there is little to do but read the deal documents, which spell out the ratio, the new company’s opening balance sheet, and whether any debt travels with the unit. On and just after the distribution date comes the dump: the index and mandate selling that pushes the price below where the fundamentals say it belongs. Then, over the first one to three quarters, the recovery begins as longer-term investors build positions and the new management’s first results start to arrive.
The three phases matter because they reward different behaviors. The investor who buys into the forced selling is betting on the mechanical recovery; the one who waits for the first quarterly report is betting on the management-improvement engine; and the one who buys a year later is paying for results that are already visible. The pitch’s own framing points at the first phase, the orphan discount, while the academic outperformance is really the sum of all three. Knowing which phase you are buying is half of knowing whether the historical edge applies to your trade.
Ready to see the research? Click here to access Gabe Marshank’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.